OPY — OPPENHEIMER HOLDINGS INC
—
NYSE ·
Financials ·
Capital Markets ·
CIK 791963 ·
Last close
$115.12
Market Cap
$1.22B
52W High
$118.60
52W Low
$90.00
ADV30
126,946
Next earnings
2026-07-31
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 445,095,000 | 142,733,000 | 100,392,000 | -20,578,000 | 3,815,278,000 | 34,601,000 | 2,849,637,000 |
| Dec 2025 | 472,630,000 | 206,308,000 | 162,730,000 | 74,362,000 | 3,722,415,000 | 38,405,000 | 2,725,386,000 |
| Sep 2025 | 424,438,000 | 127,366,000 | 85,457,000 | 21,712,000 | 3,818,148,000 | 38,288,000 | 2,897,874,000 |
| Jun 2025 | 373,178,000 | 127,063,000 | 85,281,000 | 21,674,000 | 3,687,339,000 | 37,618,000 | 2,790,481,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$90,510,000
Investing CF
$-480,000
Financing CF
$-92,125,000
CapEx
$-5,193,000
Dividends Paid
$-18,094,000
Buybacks
$-2,889,000
EPS Diluted TTM
$8.39
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$924,908,000
Inventory
—
Receivables
$1,835,671,000
ST Investments
—
EBIT TTM
$226,665,000
Pretax Income TTM
$142,814,000
Interest Exp TTM
$83,851,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,631,490,048
EBITDA
—
Free Cash Flow
—
Enterprise Value
$1,198,716,160
Total Cash
$1,458,576,000
Total Debt
$1,403,768,960
Shares Out
10,608,340
Trailing EPS
$8.39
Book Value
$88.94
ROE
10.5%
ROA
2.6%
Div Yield
0.69%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,638,071,000 | 424,259,000 | 148,403,000 | 3,722,415,000 | 2,725,386,000 | — | 188,752,000 |
| Dec 2024 | 1,432,496,000 | 304,828,000 | 71,557,000 | 3,382,726,000 | 2,532,331,000 | — | -108,168,000 |
| Dec 2023 | 1,248,825,000 | 284,178,000 | 30,179,000 | 2,874,816,000 | 2,085,577,000 | — | -18,810,000 |
| Dec 2022 | 1,110,941,000 | 199,177,000 | 32,351,000 | 2,714,392,000 | 1,893,971,000 | — | 64,492,000 |
TTM Snapshot
Revenues TTM
$1,252,709,000
NetIncome TTM
$54,897,000
OpCashFlow TTM
$0
Assets (Latest)
$3,382,726,000
Forward EPS
$2.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VRTS | VIRTUS INVESTMENT PARTNERS, INC. | $1.07B | $160.21 | — |
| ABX | Abacus Global Management, Inc. | $1.07B | $11.11 | — |
| SF-PB | STIFEL FINANCIAL CORP | $1.63B | $22.66 | — |
| BVC | BitVentures Ltd | $1.69B | $10.07 | — |
| GCMG | GCM Grosvenor Inc. | $826.04M | $13.68 | — |
News headlines (Yahoo Finance, 1h cache)
D.R. Horton Quarterly Earnings Poised for Beat Amid Multiple Tailwinds, Oppenheimer Says
2026-07-09 17:44 · Yahoo
Akamai Technology’s (AKAM) Underperformance Can Be Explained By Investors Underestimating Data Center Opportunity
2026-07-06 17:50 · Yahoo
Is Oppenheimer Holdings Inc. (OPY) A Good Stock To Buy Now?
2026-07-03 18:25 · Yahoo
Oppenheimer Sees a Long Runway for Comfort Systems (FIX)—Here’s What’s Fueling the Bull Case
2026-07-02 19:54 · Yahoo
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development
2026-06-30 13:20 · Yahoo
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?
2026-06-30 13:07 · Yahoo
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?
2026-06-30 13:06 · Yahoo
Sezzle Seen as Fast Gross Profit Grower, Oppenheimer Says
2026-06-29 15:44 · Yahoo
Aramark Poised for Solid Third Quarter Amid Revenue Outperformance, Oppenheimer Says
2026-06-29 15:11 · Yahoo
Life Time to Gain From New Centers, Higher-Priced Memberships, Oppenheimer Says
2026-06-25 15:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.